Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) Receives $2.50 Consensus Price Target from Brokerages
Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) has received an average recommendation of “Hold” from the six brokerages that are currently covering the company. Five research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $2.50.
MRNS has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 19th. Jefferies Group raised their price objective on shares of Marinus Pharmaceuticals from $2.50 to $3.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, June 28th. Royal Bank Of Canada downgraded shares of Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $14.00 to $2.00 in a report on Tuesday, June 14th. Finally, Goldman Sachs Group Inc. downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, June 14th.
Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 2.73 on Monday. The firm has a 50-day moving average price of $1.70 and a 200-day moving average price of $3.34. Marinus Pharmaceuticals has a 12 month low of $1.19 and a 12 month high of $10.24. The company’s market capitalization is $53.26 million.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.08. On average, equities analysts anticipate that Marinus Pharmaceuticals will post ($1.65) earnings per share for the current fiscal year.
In other Marinus Pharmaceuticals news, major shareholder Vii Lp Canaan sold 270,750 shares of the firm’s stock in a transaction on Monday, July 25th. The shares were sold at an average price of $1.90, for a total value of $514,425.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.00% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Franklin Resources Inc. increased its stake in shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) by 14.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,182,185 shares of the biopharmaceutical company’s stock after buying an additional 279,900 shares during the period. Franklin Resources Inc. owned 15.22% of Marinus Pharmaceuticals worth $11,740,000 as of its most recent filing with the SEC. 45.64% of the stock is currently owned by hedge funds and other institutional investors.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.